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the pathophysiology of the disease, the advances achieved 
in therapeutic results may be deemed still insufficient. 
Moreover, due to the rarity and complexity of the disease, 
the results in clinical practice are not always optimal. For 
this reason, the Spanish Group for Research on Sarcoma 
(GEIS) has developed a multidisciplinary clinical prac-
tice guidelines document, with the aim of facilitating the 
diagnosis and treatment of these patients in Spain. In the 
document, each practical recommendation is accompanied 
by level of evidence and grade of recommendation on the 
basis of the available data.
Keywords Soft tissue sarcoma · Clinical practice 
guidelines · Multidisciplinary management · Treatment
Introduction
Soft tissue sarcomas (STS) constitute an uncommon and 
heterogeneous group of tumours of mesenchymal cell ori-
gin, with an estimated incidence averaging five cases per 
100,000 per year in Europe. STS can arise anywhere in the 
body, but most originate in the extremities, less frequently 
in the trunk, retroperitoneum, head and neck and viscera. 
They can occur at any age, and although more common in 
middle aged and older adults, they are also seen in children 
and young adults. Although STS comprise of more than 
50 different histopathological subtypes, they share several 
clinicopathological features and are usually considered as 
a group for diagnostic and therapeutic purposes, with the 
exception of specific particularities of some subtypes such 
as rhabdomyosarcoma, gastrointestinal stromal tumour 
(GIST), extraskeletal osteosarcoma and Ewing sarcoma. 
STS require a multidisciplinary and complex therapeutic 
approach, involving pathologists, radiologists, surgeons, 
Abstract Soft tissue sarcomas (STS) constitute an 
uncommon and heterogeneous group of tumours, which 
require a complex and specialized multidisciplinary man-
agement. The diagnostic approach should include imaging 
studies and core needle biopsy performed prior to under-
taking surgery. Wide excision is the mainstay of treat-
ment for localized sarcoma, and associated preoperative 
or postoperative radiotherapy should be administered in 
high-risk patients. Adjuvant chemotherapy was associated 
with a modest improvement in survival in a meta-analysis 
and constitutes a standard option in selected patients with 
high-risk STS. In metastatic patients, surgery must be 
evaluated in selected cases. In the rest of patients, chemo-
therapy and, in some subtypes, targeted therapy often used 
in a sequential strategy constitutes the treatment of elec-
tion. Despite important advances in the understanding of 
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and radiation and medical oncologists, and should prefer-
ably be done in specialist centres.
In the recent years, there have been important advances 
in the understanding of the pathology and molecular biol-
ogy of this disease. However, the advances in therapeutic 
results have been quite moderate. Moreover, due mainly 
to the rarity and complexity of the disease, the results in 
clinical practice are not always optimal. For this reason, 
the Spanish Group for Research on Sarcoma (GEIS) has 
updated its multidisciplinary clinical practice guidelines, 
with the aim of facilitating the diagnosis and treatment of 
these patients [1]. These guidelines have been developed 
by a multidisciplinary group of specialists in the different 
fields involved in sarcoma diagnosis and therapy. A biblio-
graphic search of published articles was performed in the 
MEDLINE database (PubMed) and the Cochrane Library. 
Searches were limited to human studies, clinical trials, 
meta-analyses, clinical guidelines and consensus state-
ments. Additionally, a review of abstracts of relevant, still 
to be published, phase III studies focused on STS therapy 
presented at relevant international oncology meetings like 
the American Society of Clinical Oncology (ASCO) meet-
ing and European Society of Medical Oncology (ESMO) 
meeting, in the recent years, was performed. In a face-to-
face consensus meeting, the different sections, written by 
different responsible experts, were presented to the entire 
group. The members then discussed the results and deter-
mined the level of evidence and the grade for each recom-
mendation according to the ASCO guidelines [2]. The main 
objective of this document consists of providing clear prac-
tical recommendations about the different aspects involved 
in the management of this group of diseases, intended to 
help in the therapeutic decision-making processes and 
therefore contribute to improve STS patient’s care in Spain.
Warning signs and indications for referral 
to specialist sarcoma centres
The symptoms of presentation of benign and malignant soft 
tissue tumours can frequently overlap, but there are clinical 
warning signs that may help to distinguish between both 
situations: tumour size >5 cm and recent increase in tumour 
size and depth location or pain. In almost three out of four of 
cases, patients who will be diagnosed with STS have at least 
one of the four warning signs. However, delays of several 
months from the first symptom/sign until the final diagno-
sis are not uncommon [3]. For this reason, any programme 
of early reference to expert centres must take into account 
these warning signs and should design efficient access from 
primary clinical centres to sarcoma specialized ones [4].
There is much evidence to support that early recog-
nition and referral to a specialist center that provides a 
multidisciplinary diagnosis and therapeutic approach and 
treats a high number of cases annually, could improve out-
come in patients with STS. A lot of data support that the 
first diagnostic approach is critical for functional results 
and disease control in patients with sarcoma. It is recom-
mended that patients in which a STS is suspected should 
be referred to a specialized center before the biopsy is 
performed because complications and mistakes are more 
frequent in non specialized ones. The most frequent fault 
is the practice of excisional biopsies of deep tumours or 
superficial larger than 5 cm. There is a correlation between 
these procedures and the presence of affected surgical mar-
gins in the oncologic surgery (data from GEIS STS regis-
try) [5]. The impact of affected surgical margins in primary 
surgery implies a poorer local control of the disease and 
also enhances the probability of amputation [6]. Regarding 
the definition of a sarcoma referral center, the most widely 
accepted is a center with a multidisciplinary specialist team 
who holds regular committee sessions, which is composed 
of surgeons, pathologists, radiologists, radiation and medi-
cal oncologists with wide experience in STS management 
[7]. However, there are no reliable data indicating the min-
imum number of cases per year that should be treated in 
a hospital to be considered as a reference center [7]. Sev-
eral studies suggest better results in terms of local control, 
morbidity, and probably even in survival when patients are 
treated in specialized centres [7–9]. Therefore, centralized 
referral should preferably be done from the time of a sar-
coma is suspected (III, B).
Diagnostic approach to STS: imaging 
and pathology
Local staging
Magnetic resonance imaging (MRI) is the modality of 
choice in the diagnosis and local staging of soft tissue sar-
comas. MRI should be performed with intravenous contrast 
administration, and it is mandatory to obtain images in at 
least two planes. When MRI is contraindicated, contrast-
enhanced multislice computed tomography (CT) should be 
performed, preferably with sagittal and coronal reconstruc-
tions. CT can also be appropriate as a modality of choice 
in retroperitoneal soft tissue sarcomas. MRI signs that sug-
gest the diagnosis of sarcoma in a soft tissue mass includes: 
location deep to the fascia, size larger than 5 cm, and het-
erogeneity of signal intensity and contrast enhancement 
[10]. As there is some overlap in the MRI characteristics 
between soft tissue sarcomas and some benign soft tissue 
tumours, it is important to keep in mind that any lesion that 
cannot be unequivocally characterized by MRI as benign 
should be considered indeterminate, and requires biopsy.
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In a patient presenting a soft tissue mass suggestive 
of sarcoma, the MRI report should provide the following 
information of the tumour:
•	 Size.
•	 Location (superficial or deep; compartment or extra-
compartmental).
•	 Anatomical limits.
•	 Relationship with neurovascular structures.
•	 Extension of perilesional oedema.
•	 Pattern of contrast enhancement.
•	 Suggestions of areas for biopsy.
The extent of perilesional oedema detected on MRI is 
important for treatment planning because the presence 
of viable tumour cells in this area has been demonstrated 
[11]. Local tumour staging should be performed prior to 
the biopsy to prevent bleeding and inflammatory changes 
caused by the biopsy that can distort the characteristics and 
extent of the tumour on MRI. It is recommended to obtain 
radiographs of the affected region to assess the existence 
of possible calcification within soft tissue tumour, evaluate 
possible bone erosion and exclude a bone tumour.
Distant staging
Chest radiographs (frontal and lateral) and multislice chest 
CT are indicated in all cases of STS to rule out pulmo-
nary metastases. Abdominal CT is indicated in the cases of 
myxoid liposarcoma of the extremities, given the high fre-
quency of synchronous distant lesions in this histological 
subtype. The clinical benefit of performing an abdominal 
CT scan in cases of epithelioid sarcoma, synovial sarcoma, 
angiosarcoma and leiomyosarcoma should be assessed 
individually in each case. MRI study of the spine may be 
necessary in cases of myxoid liposarcoma due to its ten-
dency to develop extrapulmonary metastases, and the limi-
tations of bone scan or even positron emission tomography 
(PET) in the detection of spinal metastases in this histologi-
cal subtype [12]. PET usefulness is limited to the detection 
of malignant transformation of neurofibromas in patients 
with neurofibromatosis type 1 [13], and in distant staging 
for cases of local recurrence of STS in which aggressive 
salvage surgery is considered.
Biopsy
Percutaneous core needle biopsy (CNB), also known as 
“tru-cut biopsy”, is currently recommended for STS diag-
nosis [14], because it is minimally invasive and will not 
limit subsequent surgical interventions. Its accuracy is sim-
ilar to that of the incisional biopsy, with the added benefit 
that it does not require hospitalization.
In the largest series of patients, CNB had a sensitiv-
ity of 99.4 % and a specificity of 98.7 % in the diagno-
sis of malignancy (sarcoma versus benign mesenchymal 
tumour) [14]. These percentages are very similar to those 
achieved with the incisional biopsy. In the same way, CNB 
may properly identify histological subtype and grade in 
80 % of the cases [14]. It is recommended to perform the 
biopsy in the same hospital where the patient is treated, 
either by radiologists or surgeons trained in the practice of 
these procedures. Close cooperation with the pathologist is 
mandatory.
The use of radiological techniques to guide the CNB, 
mainly ultrasound and CT, has substantially improved 
diagnostic procedures. Image guidance allows more pre-
cise tumour location and helps to guide the biopsy to those 
areas of viable tumour. In selecting the areas for biopsy, it 
is essential to avoid cystic, necrotic or hemorrhagic tumour 
areas. Imaging studies should also be carefully evaluated 
to identify more aggressive areas (which usually show a 
higher degree of contrast enhancement) in order to define 
the tumour grade more accurately. The most commonly 
used CNB are between 14 and 18 G. In a recent review, 
the accuracy of this type of biopsy was not influenced by 
the gauge of the needle used [15]. In contrast, the number 
of biopsy passes (equal or above 4) and the length of the 
biopsy specimen obtained are factors that increase the diag-
nostic yield of CNB [15]. When planning a percutaneous 
biopsy, it is mandatory to avoid non-involved anatomical 
compartments, and it should be noted that the path of the 
biopsy and the scar should be resected by definite surgery. 
Hemostatic problems also must be corrected prior to the 
biopsy, due to the risk of tissue contamination caused by 
post-biopsy hematomas. STS are heterogeneous tumours, 
and a small sample obtained by this type of biopsy may 
underestimate the histological grade. Thus, unless a high 
degree appears in the percutaneous biopsy, definitive his-
tological grade will be established in the surgical specimen. 
Due to the limitation on the size of the sample obtained by 
percutaneous biopsy, sometimes it is not possible to estab-
lish with certainty the histological diagnosis. In these situa-
tions, it may be necessary to perform incisional biopsy (III, 
B).
Pathology and molecular pathology
Appropriate clinical information should be available for a 
correct interpretation of the initial biopsy. It is advisable in 
patients referred from other hospitals to ask for the biopsy 
material and/or surgical specimen for histological review 
and confirmation. In general, the core needle biopsy (tru-
cut) is the diagnostic method of choice. Fine-needle aspi-
ration cytology (FNA) is not recommended as the initial 
diagnostic procedure except in some centres with extensive 
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experience. FNA is, however, suitable to confirm the pres-
ence of recurrence or metastasis of a sarcoma already 
known, and can be useful in some cases of round cell sar-
coma, since molecular techniques may be performed on 
tumour imprints (touch preps).
Whenever possible and when it does not interfere with 
the diagnosis, it is recommended to freeze and preserve 
tumour fragments, and samples for cytogenetics (tumour 
imprints on slides pre-treated for immunohistochemistry), 
as well as liquid samples (plasma, serum) in biobanks. To 
avoid degradation of the tissue, the interval between biopsy 
and freezing should not exceed 30 min. The availability of 
a blood sample could add to the value of tumour tissues. 
Informed consent for biobanking should be obtained, ena-
bling later analyses and research, as long as this is allowed 
by local and international rules.
Pathological diagnosis of soft tissue sarcomas
It is mainly based on morphology and immunohistochem-
istry. It must be in accordance with the 2013 World Health 
Organisation sarcoma classification [16]. This integrates 
morphological and immunohistochemical data, together 
with molecular cytogenetics. The histological tumour grade 
should be determined when possible; we recommend the 
system of the Fédération Nationale des Centres de Lutte 
Contre le Cance (FNCLCC), which is based on the evalu-
ation of three histological parameters (tumour differentia-
tion, mitotic index and percentage of necrosis), and defines 
three histological grades. In some sarcomas, histological 
type itself determines the aggressiveness of the tumour, and 
the histological grade does not provide additional prognos-
tic information. Immunohistochemical study is useful to 
determine the type of tumour differentiation (muscle, neu-
ral, etc.), and, in turn, to rule out non-mesenchymal tumour 
types (carcinoma, melanoma, lymphoma…); but it does not 
provide information about the classification of the tumour 
as benign or malignant.
Indication of molecular studies
Use of molecular techniques is not necessary for the diag-
nosis of all cases of sarcomas. Molecular studies should be 
performed especially when:
•	 specific histological diagnosis is doubtful
•	 clinicopathologic presentation is unusual
•	 it may have prognostic/predictive relevance.
In the case of STS, the aim of the molecular study is to 
detect the presence of chromosomal translocations and gene 
fusions/gene rearrangements by the reverse-transcriptase 
polymerase chain reaction (RT-PCR) or fluorescence in situ 
hybridization (FISH).
Pathology report
Regarding the tru-cut (core needle) biopsy, in most cases 
it allows classification of the tumour (histology) and pro-
vides the degree of malignancy. The pathology report of 
a tru-cut biopsy should include histological type (when 
not possible it may be useful to try to classify in the cat-
egories of spindle cell, pleomorphic, myxoid, epithelioid 
or round cell), histological grade and the results of any 
additional tests that have been made (immunohistochem-
istry and/or molecular biology) [17]. One limitation of the 
core biopsy is that it can miss a small high-grade region 
in a heterogeneous tumour. Therefore, when preopera-
tive treatment is an option, radiological imaging may be 
useful in addition to pathology, in providing the clinician 
with information that helps to estimate the tumour grade 
(i.e. necrosis).
The pathology report of a resected specimen of sar-
coma should include, in addition to the histological type 
and tumour grade, tumour description (size, location, per-
centage of necrosis and hemorrhage and relationship to 
adjacent structures), status of resection margins, satellite 
nodules and lymph nodes. An appropriate sampling of the 
tumour should be made; it is generally recommended to 
select a section for each centimetre of tumour diameter. In 
very large tumours, 10–12 blocks can be enough. The sec-
tions on the margins should be at right angles. The report 
should also include the result of the immunohistochemical 
and molecular studies, if performed.
Treatment of localized disease
Surgery
Surgery is the mainstay of treatment in localized STS. 
Although they are a heterogeneous group of neoplasms, the 
main principles of surgery are common to them all. Surgi-
cal treatment should be performed by expert surgeons and 
should be based on consensus decisions taken on a multi-
disciplinary board.
Wide excision of the tumour is the base of surgical treat-
ment of STS, which implies en bloc resection of all the 
neoplasm, the neocapsule (or reactive peritumoural tissue) 
and a variable layer of surrounding healthy tissue, called 
surgical margin. It is not possible to define the standard 
surgical margin, because it depends on several factors: 
tumour size, tumour location (intra or extracompartmental), 
the anatomical compartment implied, histological grade, 
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proximity to neurovascular structures and the previous 
treatments performed.
Depending of the characteristics of surgical margin, sur-
gery can be classified into:
•	 Intralesional only accepted as a diagnostic biopsy (inci-
sional biopsy).
•	 Marginal includes peritumoural reactive tissue, but not 
healthy tissue margins.
•	 Wide includes an appropriate margin of healthy tissue 
free of tumour. However, the presence of the fascia, 
perineurium, periosteum and vascular adventitia free of 
tumour are considered as adequate margins.
•	 Radical includes all the anatomical compartment in 
which STS has grown.
•	 Contaminated a surgical procedure of STS should be 
considered contaminated if sarcomatous tissue remains 
exposed during surgery. In these cases, local spread of 
malignancy could occur.
In bloc surgery with wide or radical margin is the right 
treatment, but marginal surgery could also be accepted in 
some cases of low-grade STS with extracompartmental 
location (for example, atypical lipoma).
Enneking, Spanier and Goodman have contributed to 
the improvement of the knowledge and efficacy of surgical 
procedures in STS by defining the concept of anatomical 
compartments as a close unit where the tumour is confined, 
allowing surgeons to plan the surgery better from oncologi-
cal point of view [18]. The following list defines compart-
mental and extracompartmental locations of STS (Table 1).
Surgery of STS must be carefully planned, taking into 
account the results of imaging and biopsy (STS subtype 
and grade). Unplanned surgery is unacceptable, and it is 
one of the main causes of local failure.
Surgical procedure can be performed through ischae-
mia technique, but pneumatic cuff should be far from 
the tumour, and sanguinea expression should be avoided. 
Elevation of extremity for 10 or 15 min will provide suf-
ficient blood emptying. Regarding skin incision, it should 
always be performed on the direction of longitudinal axis 
of the member affected and should also include biopsy or 
aspiration cytology scar and previous drainage path. Once 
tumour excision is completed, the ischaemia system is 
removed, and two important technical aspects should be 
carried out: complete hemostasis (which reduces the risk 
of hematoma appearance and healing delays) and place-
ment of suction drain system (following the longitudinal 
axis of the incision and as much closer to it as possible). 
Thorough washing of the tumour bed is mandatory to 
minimize infectious complications, mainly because these 
kinds of surgeries tend to be long and harmful for tissues. 
Inserting metal clips (titanium is preferred) before closing 
is recommended, in order to properly localize the surgical 
tumour bed. After that, closing of the defect can be per-
formed trying to avoid empty spaces in the surgical bed, 
and a weak pressure bandage can also be placed to ensure 
a good tissue recovery. Moreover, surgical specimen has to 
be marked to help pathologist to identify surgical margins 
properly. However, if contamination of the surgical field 
occurs during surgery, some procedures have to be done: 
close the gap opened in the tumour by suture, change sur-
gical instruments, expand surgical margins and report it 
because it will be taken account at the time of planning 
adjuvant treatments.
Salvage surgery and amputation
Adequate surgery with extremity preservation is usually 
possible in the vast majority of STS. However, amputa-
tion or disarticulation should be planned for the following 
scenarios:
•	 When free margins cannot be ensured with conservative 
surgery and they are tried to be obtained with more radi-
cal surgery.
•	 When wide infiltration of neurovascular bundles exists.
•	 When properly functional reconstruction is not feasible 
or the result is, at least, the same as conservative sur-
gery.
If after STS surgery margins are not free, this initial sur-
gery is considered suboptimal and, as a consequence and 
if it is possible, re-surgery should be planned in order to 
expand margins.
Surgery for expanding margins must be more radical, 
and therefore, reconstruction procedures tend to be more 
complex [19–21].
If after an initial STS treatment a local recurrence 
occurs, salvage surgery can be performed. However, before 
Table 1  Soft tissue sarcoma: compartmental and extracompartmental 
locations
Compartmental Extracompartmental
Hand–foot radius Midfoot and hindfoot
Rear leg Popliteal space
Anterolateral leg Scarpa triangle
Anterior thigh Intrapelvic region
Medial thigh Hand palm
Posterior thigh Antecubital fossa
Gluteal region Axilla
Anterior forearm Periclavicular area
Posterior forearm Paraspinal region
Periscapular Head and neck
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planning it, it is important to properly evaluate the exist-
ence of a possible multicentric recurrence and/or metastatic 
disease.
In general terms, recurrence surgery is more compli-
cated and more aggressive (and the resection must include 
drain path drainage of previous surgery). In this situation, 
the percentage of amputations increases and reconstruction 
procedures are more often needed [22].
Radiotherapy
Adjuvant radiotherapy (RT) is offered in addition to con-
servative surgery to optimize local control. There are two 
prospective randomized trials, one using brachytherapy 
(BRT) ant the other postoperative external beam RT 
(EBRT), which demonstrated the local control advantage 
of adjuvant RT over surgery alone in sarcomas [23, 24]. 
The study used EBRT, randomized 141 patients (91 with 
high-grade tumours, 38/91 < 5 cm, 50 with low-grade 
tumours, 16/50 < 5 cm) to receive or not receive postop-
erative RT [23]. In this prospective randomized trial, adju-
vant postoperative EBRT was shown to result in a statisti-
cally significant reduction in local recurrences in patients 
with either high-grade or low-grade extremity tumours, 
without significant differences in overall survival. The 
conclusions of this study are pertinent only to patients 
who undergo a satisfactory local excision with negative 
or minimal microscopically positive resection margins. 
A second study evaluated post-operative BRT, randomiz-
ing 164 patients to BRT or no further treatment [24]. The 
improvement in local control was limited to patients with 
high-grade lesions and was not associated with a signifi-
cant reduction in distant metastasis or improvement in 
disease-specific survival.
Post-operative and pre-operative EBRT have also been 
compared with each other in a randomized manner. The 
National Cancer Institute of Canada (NCIC) trial compared 
50 Gy in 25 fractions pre-operatively and 66 Gy in 33 frac-
tions post-operatively [25]. They accrued 182 evaluable 
patients (31 low-grade STS, 151 high-grade STS) for which 
eligibility criteria was the need for combined radiotherapy 
and surgery, that is, if tumour could not be excised with 
a minimum of 2 cm of healthy tissue or an intact fascial 
plane. The primary endpoint was the presence or absence of 
a major wound complication. Of the pre-operatively irradi-
ated patients, 35 % showed wound complications compared 
with 17 % in the post-operative RT group (p = .01). No dif-
ference was found between the two groups in local control, 
progression-free or overall survival, although the study was 
not powered to evaluate these end points. Interstitial BRT 
has been demonstrated to be an effective method of deliv-
ering adjuvant RT, within a considerably shorter treatment 
time than EBRT, and with potentially smaller treatment 
volumes [24]. However, its relatively limited use could be 
attributed to lack of effectiveness in low-grade histology, 
and it is a complex and labour-intensive technique.
Regarding some specific technical issues, preopera-
tive RT is delivered in once-daily 1.8- to 2-Gy fractions 
to a total dose of 50–50.4 Gy. The entire dose is pre-
scribed to a single planning target volume (PTV). In the 
case of postoperative RT, a portion of the dose is ordinar-
ily applied to a larger volume encompassing the surgical 
bed with appropriately safe margins. A careful review 
of the surgical and pathology reports is essential to opti-
mally define the target volume and the dose level to be 
administered. Commonly applied doses are 45–50.4 Gy 
in once-daily 1.8- to 2-Gy fractions. This is followed 
by a smaller volume boost to the tumour bed. Typically, 
doses of 14–18 Gy are applied, resulting in a total dose of 
63–66 Gy. The guidelines to construct the RT volumes are 
available [26, 27].
When RT can be administered with minimal toxicity, its 
significant contribution to local sarcoma control following 
limited resection is of value. When the expected toxicity of 
RT is high and the risk of local recurrence is predicted to be 
low (based on surgical margins, tumour size), surgery with-
out adjuvant RT may be the treatment of choice. Specific 
recommendations are: wide excision is followed by radia-
tion therapy as standard treatment of deep and high-grade 
(G2–3) STS (II, B). Radiation therapy is added in selected 
cases in the case of high-grade, superficial lesions or in the 
case of low-grade, deep, >5 cm lesions. Radiation therapy 
is added in selected cases in the case of low-grade, super-
ficial, >5 cm and low-grade, deep, <5 cm lesions (II, B). 
Radiotherapy may be carried out pre-operatively or post-
operatively (I, A).
Adjuvant chemotherapy
The use of adjuvant chemotherapy has been studied 
in several clinical trials because of the risk of metasta-
sis which is close to 50 % in the group of patients with 
high-risk STS. These studies, however, often provide 
conflictive results. Variations in the chemotherapy sched-
ules and the selection criteria used in the different stud-
ies could partially explain the disparity in the results. A 
recent meta-analysis included a total of 18 phase III tri-
als comparing adjuvant chemotherapy versus observation 
in resected localized STS. The regimens used included 
doxorubicin or epirubicin, associated with ifosfamide in 
five trials. The results showed that chemotherapy was 
associated with a risk reduction in overall recurrence of 
10 % and an improvement in overall survival of 6 %. 
Moreover, the results suggested that the association 
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of anthracyclines and ifosfamide is associated with an 
improved benefit [28].
A previous meta-analysis, including 14 trials, showed a 
greater benefit in the group of patients with extremity sar-
comas [29]. A recent trial focused on patients with high-
risk STS (high-grade, deep location and >5 cm) located in 
the extremities and girdles. The chemotherapy schedule 
included high doses of epirubicin and ifosfamide. After a 
median follow-up of 5 years, overall survival was signifi-
cantly higher for patients treated with adjuvant chemother-
apy [30], although that difference decreased after a longer 
follow-up [31]. Another trial, performed by the Euro-
pean Organization for Research and Treatment of Cancer 
(EORTC) not included in the above-mentioned meta-anal-
ysis, involved patients with high- and intermediate-grade 
STS at any site. The adjuvant chemotherapy consisted of 
doxorubicin and ifosfamide versus placebo. No differences 
in survival between both arms were found [32]. Neverthe-
less, an update of the meta-analysis including this study 
showed a difference in overall survival favouring adjuvant 
chemotherapy with a hazard ratio of 0.86 (95 % CI 0.79–
0.97) [32].
Consequently, data from meta-analysis indicate that 
adjuvant chemotherapy using anthracycline-based regi-
mens provides a significant, although limited, improve-
ment in relapse and survival in patients with high-risk STS. 
For this reason, it constitutes a standard option of treat-
ment in selected patients (IA). Its administration should 
be only considered in those patients with high-grade, 
deep and >5 cm tumours, especially if they are located in 
the extremities (IIA). However, close observation without 
chemotherapy administration is also a standard option, 
given its limited benefit and the risk of associated tox-
icity (IA). The decision of whether to treat or not should 
be made in each individual case, after discussion with the 
patient of potential benefits and risks. If chemotherapy is 
administered, a regimen including doxorubicin and ifos-
famide is recommended (IIA). For patients younger than 
65 years, the Frustaci and col. regimen [31] is recom-
mended (IIB). The standard recommendation consists of 
five cycles, but the results of a recent randomized trial of 
neoadjuvant chemotherapy suggest that, in a perioperative 
setting, a total of three cycles could be enough [33] (IIB). 
Adjuvant therapy is particularly not recommended for the 
low-grade sarcomas, those <5 cm, retroperitoneal and vis-
ceral sarcomas and subtypes not sensitive to chemotherapy 
(IIB). In the absence of further data, the EORTC 62931 
trial suggests that delaying the administration of radiother-
apy until completion of adjuvant chemotherapy is not asso-
ciated with a worse local control [32] but has the potential 
advantage of not compromising the optimal chemotherapy 
administration (IIB).
Neoadjuvant chemotherapy with or 
without radiotherapy and response assessment
The number of studies regarding neoadjuvant chemother-
apy in STS is limited, and most of them are small series 
and phase II trials. A randomized phase II trial compared 
three cycles of neoadjuvant chemotherapy with doxoru-
bicin and ifosfamide versus surgery alone in high-risk STS. 
The study did not demonstrate any benefit of neoadjuvant 
chemotherapy in terms of survival or in relapse-free sur-
vival [34]. Recently, a randomized non-inferiority phase 
III study compared three cycles of pre-operative chemo-
therapy with epirubicin and ifosfamide versus the same 
regimen plus two additional adjuvant cycles of treatment 
after surgery. The results showed that three cycles were not 
inferior to five cycles in terms of recurrence and survival 
[33]. Additionally, several non-comparative phase II trials 
showed the feasibility of concurrent neoadjuvant chemo-
radiotherapy with different regimens and provided prom-
ising results [35]. This strategy, giving the demonstrated 
activity of preoperative radiation [25], is being widely stud-
ied at present.
Therefore, despite the current setting of shortage of evi-
dence, some practical recommendations regarding neoadju-
vant therapy in STS may be made. It could be considered 
as an option in those cases with large STS that are margin-
ally resectable or require very aggressive surgery without 
assuring clean margins (III B). In those cases, probably the 
combination of pre-operative radiation and chemotherapy 
might have advantages over either modality alone (IVB). 
Additionally, potential benefits of neoadjuvant chemo-
radiotherapy in patients with high-risk STS could be early 
treatment of micrometastases, shrinking the tumour, facili-
tating surgery and testing in vivo tumour chemosensitivity. 
Nevertheless, in this population neoadjuvant chemotherapy 
with or without radiotherapy remains investigational.
Concerning radiological and pathological response 
assessment to neoadjuvant therapy, some specific consid-
erations should be addressed. MRI is the imaging modality 
of choice in the assessment of response in these patients. 
The assessments of the volume or the signal intensity of the 
tumour by MRI are not reliable criteria of response to neo-
adjuvant therapy since the tumour volume increase may be 
due to oedema and hemorrhage changes in cases of good 
response, whereas a reduction in tumour volume is usually 
not obtained even in cases with good response. Contrast-
enhanced dynamic MRI is a technique that is being actively 
studied in the assessment of response to neoadjuvant ther-
apy. However, at present its use remains experimental. On 
the other hand, pathological response to neoadjuvant ther-
apy could be evaluated in the resected specimen. Percent-
age of necrosis of 95 % at least (similar to that used in bone 
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sarcomas) is usually recommended, but data regarding 
this issue are controversial [36]. Nevertheless, decreased 
cellularity and fibrosis also should be taken into account 
together with necrosis.
Role of isolated limb perfusion
Hyperthermic isolated limb perfusion (ILP) is a therapeu-
tic approach that can be planned in STS when optimal 
conservative surgical procedure is not feasible, either due 
to tumour or patient comorbidity. It allows the administra-
tion of much higher doses of chemotherapy avoiding the 
systemic toxicity. ILP in hyperthermia is a technique in 
which the circulation of the limb where STS is located is 
cut off from the rest of the organism through an extracor-
poreal circuit and treated with biocytotoxic agents. The liq-
uid administered is at a higher temperature than the rest of 
the body (39 °C), intensifying its effect. The administration 
of tumour necrosis factor alpha (TNF-α) and melphalan 
has improved the responses [37, 38]. Two recent reviews 
have analysed the results of several studies including 518 
patients with STS treated with ILP. The overall response 
rate was 70 %, and the rate of patients in whom limb-spar-
ing surgery was possible was also 70 %, although the num-
ber of local and systemic relapses was high. However, these 
reviews showed that an improved standardization of meth-
odology in studies that evaluate ILP is needed [39, 40]. 
Therefore, hyperthermic ILP with TNF-α and melphalan 
constitutes an option. It may be considered in patients with 
limb STS where conservative surgery is not feasible, in 
order to carry out subsequent surgery preserving limb func-
tion (III, B) and patients with disseminated STS in whom 
local surgery is contraindicated, but local palliative control 
is necessary (III, B).
Treatment of metastatic disease
With current appropriate management, local control of 
STS is achieved in around 80–90 % of patients. However, 
approximately half of all patients with high-grade tumours 
will develop metastatic disease and most of them will die 
from it.
Surgery
Patients with exclusive pulmonary metastasis should be 
evaluated for surgery. The decision of metastasectomy 
should be based on disease-free period following primary 
surgery (ideally greater than one year) and total number of 
lesions (III, B). Complete resection of pulmonary metasta-
ses in the group of selected patients with these favourable 
prognostic features achieves up to 20 % long-term survival 
[41–45]. Prior restaging should be performed to rule out 
local recurrence or other sites of metastases. There is no 
clear evidence of benefit associated with the administration 
of adjuvant chemotherapy after resection of metastases in 
STS. In contrast, in patients with synchronous lung metas-
tases, short disease-free interval or high number of lesions, 
chemotherapy should be the initial treatment. Subsequent 
surgery if benefit is achieved from chemotherapy, however, 
could be an option (IV, C).
Chemotherapy and targeted agents
First‑line treatment (doxorubicin and ifosfamide)
Doxorubicin and ifosfamide are the most active drugs and, 
given sequentially or in combination, constitute the stand-
ard treatment for advanced STS [46] (I, A). The association 
of doxorubicin and ifosfamide increased the response rate 
and toxicity but did not improve survival in randomized 
trials [47, 48] (I, A). High doses of ifosfamide (>10 g/m2) 
and doxorubicin regimens with GCSF support are also 
associated with increased response and toxicity but did not 
show improvement in survival in randomized trials [49, 50] 
(I, A). Therefore, the recommended first-line treatment is 
doxorubicin at 75 mg/m2. Epirubicin could also be an alter-
native to doxorubicin. Ifosfamide constitutes an alternative 
for contraindication of doxorubicin or a second-line treat-
ment after doxorubicin failure. Ifosfamide in monotherapy 
is used at doses of 5–9 g/m2, although some data suggest 
that the higher doses are the most active. However, the use 
of a combination regime of both drugs could be justified 
when obtaining an objective response to improve symp-
toms or when performing surgery is important (III, B). 
Interestingly, some data suggest these could be some dif-
ferences in the sensitivity to chemotherapy according to the 
different histological subtypes. For this reason, at present 
several studies are being performed on specific subtypes.
Second‑line chemotherapy and beyond
Second-line therapy for advanced or metastatic unre-
sectable disease is always palliative. Thus, close clinical 
observation may be an option for asymptomatic patients, 
especially for those with low-grade tumours or known low 
responsive entities. For symptomatic patients with poor 
performance status, radiotherapy or best supportive care 
alone is appropriate options. Symptomatic patients with 
good performance status are good candidates for clinical 
trials. Outside the context of clinical trials, conventional 
systemic therapy should be offered.
Trabectedin has been broadly explored in several phase 
I–II trials. Although the objective response rates were 
modest, a higher progression arrest rate was observed, 
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especially in liposarcoma (notably myxoid liposarcoma, 
88 %) [51], synovial sarcoma and leiomyosarcoma, but 
also in other tumour types. Tumour response had a par-
ticular pattern with early decrease in tumour density on 
CT or decrease in MRI contrast enhancement, followed by 
delayed tumour shrinkage. A randomized phase II trial in 
previously treated advanced liposarcoma or leiomyosar-
coma comparing trabectedin infusion 1.5 mg/m2 over 24 h 
every 21 days versus a weekly scheme over 3 h demon-
strated the superiority of the 24-h infusion in terms of time 
to progression [52]. Based in these studies, trabectedin was 
approved in Europe for patients with STS after progres-
sion to doxorubicin and ifosfamide or in patients ineligible 
for these treatments. The preliminary results of a recently 
reported phase III trial showed that trabectedin improves 
disease control in comparison with the classically stand-
ard second-line DTIC, in advanced pre-treated metastatic 
liposarcoma or leiomyosarcoma [96] (I, A). Premedication 
with dexametasone and administration through a central 
venous access device are recommended.
Gemcitabine has been evaluated in several phase II tri-
als showing limited activity (II, B). If used, a fixed dose 
rate infusion (10 mg/m2/min) is usually recommended. 
DTIC alone has also limited activity, with 18 % short living 
responses [53]. However, the superiority of the combina-
tion of gemcitabine (1800 mg/m2 at 10 mg/m2/min) with 
DTIC (500 mg/m2) every 14 days versus DTIC alone has 
been reported in a randomized phase II trial in terms of 
median progression-free survival (PFS) and overall survival 
(OS), with a favourable toxicity profile [54]. The benefit of 
this combination appears to be more pronounced in leio-
myosarcoma, although other subtypes may also benefit (II, 
B). Docetaxel in monotherapy is not active in STS, but in 
combination with gemcitabine has demonstrated interesting 
responses, especially in uterine leiomyosarcoma. A multi-
centric randomized phase II trial showed response rates of 
16 versus 8 % and superior median PFS and median OS 
for the combination versus gemcitabine alone [55]. Patients 
with leiomyosarcoma and undifferentiated pleomorphic 
sarcoma appeared to be benefitted the most, but at the 
expense of greater toxicity. Contradictory results have been 
reported in another small phase II trial, particularly for 
non-uterine leiomyosarcomas [56] (II, C).
A randomized double-blind phase III study (the PAL-
ETTE trial) [57] comparing pazopanib (800 mg daily) ver-
sus placebo in 369 patients with non-adipocitic sarcomas 
progressing after first-line chemotherapy (including an 
anthracycline) showed a benefit in median PFS and disease 
stabilization favouring pazopanib (4.6 vs. 1.6 months, 67 
vs. 38 %, respectively) with no significant difference in OS. 
All the included subtypes seemed to benefit to the same 
extent. Given the risk for serious hepatotoxicity, close mon-
itoring of liver function tests is recommended, particularly 
in the first nine weeks of therapy (basal, week 3, 5, 7 and 
9). Pazopanib constitutes an appropriate option after first 
line or thereafter progression in non-adipocitic sarcoma (I, 
A).
Additionally, a dose–response relationship has been 
shown for ifosfamide. Therefore, patients who have previ-
ously received ifosfamide may be treated with high-dose 
ifosfamide (>10 g/m2) [58] (III, B). Particular sensitivity 
has been reported for synovial sarcoma. Its main toxicities 
are hemorrhagic cystitis, renal and central nervous system 
toxicity. Concurrent administration of the uroprotectant 
mesna and appropriate hydration decreases the incidence of 
hemorrhagic cystitis.
For the majority of STS, there is no evidence that a par-
ticular drug sequence is better than another and probably 
most patients with good performance status benefit from 
being exposed to the largest number of available drugs (IV, 
C). As previously stated, some tumour types are specially 
sensitive to certain drugs, and this fact could help to select 
the second-line therapy, for example: high-dose ifosfamide 
for synovial sarcoma, trabectedin for myxoid liposarcoma 
and leiomyosarcoma, gemcitabine with docetaxel or with 
DTIC in leiomyosarcoma.
Therapeutic considerations for specific STS 
subtypes
Retroperitoneal sarcomas
Retroperitoneal sarcomas (RPS) are characterized by poor 
prognosis. More than half are high grade and adequate sur-
gical margins are rarely obtained. The standard imaging 
procedure is a chest–abdominal CT scan. Fine-needle aspi-
ration is not adequate for primary diagnosis. An extraperi-
toneal biopsy via core needle is the procedure of choice. 
Nevertheless, it is reasonable to avoid biopsy in the case of 
a resectable retroperitoneal mass with a clear-cut CT scan 
indicating adipocitic well-differentiated liposarcoma.
En bloc resection of the tumour including adjacent 
organs is the only curative treatment for RPS, negative 
margins being the main prognostic factor (IV B) [59]. Post-
operative radiation is an option in highly selected patients 
with well-defined target regions (IV B) [60]. Adjuvant 
and neoadjuvant chemotherapy should not be routinely 
employed in RPS due to lack of evidence of benefit (IV B).
Uterine sarcomas
Uterine sarcomas (US) are composed of different tumour 
entities: leiomyosarcomas, high-grade uterine sarcoma and 
sarcomas of endometrial stromal origin. Carcinosarcomas 
behave like epithelial carcinomas and are not covered by 
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the following guidelines. Standard surgery of localized 
US consists of total abdominal hysterectomy plus double 
oophorectomy and full abdominal cavity exploration. It is 
not clear whether bilateral oophorectomy is always needed, 
particularly in low-grade US. Lymphadenectomy is not 
indicated. If an unsuspected US is diagnosed after surgery, 
a second-look intervention is not recommended if a total 
hysterectomy has been performed and macroscopic tumour 
does not remain. Adjuvant radiotherapy is controversial. 
Most available clinical trials are not optimally designed but 
tend to show a decrease in local relapse risk. No trial has 
proven an overall survival advantage [61]. Thus, adjuvant 
radiotherapy it is not routinely considered, but it is justi-
fiable in selected cases with a high relapse risk (II, C). A 
clinical trial comprising a small number of patients with 
uterine leiomyosarcoma showed a benefit of adjuvant gem-
citabine plus docetaxel compared with historical controls 
[62]. There is not enough evidence to recommend adjuvant 
chemotherapy, but it could be individually planned in some 
patients (III B).
Hormonal therapy with megestrol acetate, gonadotro-
pin-releasing hormone (GnRH) analogues and aromatase 
inhibitors can delay progression for long periods of time in 
low-grade oestrogen receptor-positive endometrial stromal 
sarcoma, and it is preferred over chemotherapy as front-line 
palliative treatment (IV, C). Doxorubicin, ifosfamide, gem-
citabine, taxanes, and trabectedin are active against US. We 
recommend a cautious approach favouring less toxic mon-
otherapy options in the first place (IV, B). Positive results 
have been published for leiomyosarcoma patients treated 
with gemcitabine plus docetaxel as first- or second-line 
treatment [63]. It is acceptable to select either doxorubicin 
or this regime as first-line palliative chemotherapy (III, B).
Desmoid tumours
Desmoid tumours (DT) represent a mesenchymal neoplasm 
of intermediate behaviour. They rarely metastasize, but 
show a marked tendency to local relapse with progressive 
increasing aggressivity. Surgery remains the mainstay of 
DT curative treatment. It is usually straightforward in the 
case of limb and chest-wall tumours, but can be much more 
challenging in abdominal disease. The aim of surgery is the 
macroscopic removal of the whole tumour while minimiz-
ing morbidity. Wide margins, even microscopically nega-
tive ones, do not justify on their own mutilating surgeries 
or functional sequels, as the prognosis of macroscopically 
resected (R1) patients do not depend on the microscopi-
cal status of the margins [64] (III, A). A watch-and-wait 
approach is also acceptable in the case of small, non-
growing, asymptomatic extraabdominal tumours that do 
not impose a significant risk for nearby critical organs or 
structures. Non-treatment decisions should not be taken in 
the absence of a diagnostic biopsy (IV, B).
Radiotherapy is able to control even bulky disease for 
long periods of time [65]. It is recommended in several 
scenarios like unresectable tumours, R2 surgery, patients 
refusing surgical treatment, serious comorbidity that makes 
surgery too risky or cases in which radical surgery would 
impose serious functional or cosmetic sequels (III, B). Sys-
temic treatment is appropriate for unresectable tumours, 
Gardner-related cases with multiple recurring DT, progres-
sions in areas previously irradiated and functionally or aes-
thetically unacceptable surgery. Evidence-based options 
include non-steroidal anti-inflammatory drugs like sulindac 
(IV, D), anti-oestrogens (tamoxifen and toremifene) (IV, 
D), chemotherapy (low-dose methotrexate plus vinblas-
tine or vinorelbine and liposomal doxorubicin) (III, B) and 
imatinib [66] (III, B).
Angiosarcoma
Angiosarcoma (AS) is a heterogeneous type of sarcoma 
due to its age of presentation and location. Sometimes it is 
multifocal and can be associated to anaemia and coagulop-
athy [67–69] ]. The treatment of choice of localized AS is 
complete excision with wide margins. Adjuvant radiother-
apy is recommended if optimal surgery is not feasible due 
to multifocality or difficulty in defining the true margins 
[67, 68] (IV, B). In advanced AS, systemic chemotherapy 
with either anthracyclines or taxanes are acceptable treat-
ment options (II B). However, in the AS of the scalp, fre-
quently seen in elderly patients, weekly paclitaxel is the 
drug of choice because it seems to have better response rate 
than anthracyclines [70–72]. Anti-angiogenic drugs like 
bevacizumab and sorafenib have also been tested in meta-
static AS with promising activity [73, 74] (III, B).
Alveolar soft part sarcoma
Alveolar soft part sarcoma (ASPS) often occurs in adoles-
cents and young adults. Complete excision with wide mar-
gins is the treatment of choice. The administration of adjuvant 
radiotherapy follows the common guidelines for STS (IV, B). 
ASPS is not particularly sensitive to classic chemotherapeu-
tic agents used in STS. However, ASPS has an upregulation of 
angiogenesis elements, and cediranib has proven to be active 
in advanced disease [75]. Several partial responses to sunitinib 
and bevacizumab have also been reported [76, 77] (IV, B).
Dermatofibrosarcoma protuberans
Dermatofibrosarcoma protuberans (DFSP) is a cutaneous 
mesenchymal tumour of intermediate behaviour. Although 
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DFSP metastasize exceptionally, it has an important local 
infiltrative ability. In cases of localized DFSP complete 
resection with wide margins (2–4 cm) is the treatment of 
choice. Mohs surgery can be planned to avoid major cos-
metic defects (III B). Adjuvant radiation therapy should be 
considered when margins are positive and re-resection is 
not feasible [78–80] (IV, B). In unresectable, recurrent or 
metastatic DFSP, imatinib is recommended (III B) [81].
Clear cell sarcoma
Clear cell sarcoma (CSS) tends to metastasize to lymph 
nodes, unlike other STS. In localized CCS, wide surgical 
resection is the mainstay of treatment. Elective lymphad-
enectomy or sentinel node biopsy could be also considered 
(IV C). Lymphadenectomy should be performed in cases of 
lymph node metastasis (IV B). The administration of adju-
vant radiotherapy follows the common guidelines for STS 
(IV, B). In advanced CSS, response rate to chemotherapy is 
generally low [82–84]. However, some isolated responses 
have been described with antiangiogenic agents such as 
sorafenib or sunitinib [85, 86] (V, D).
Solitary fibrous tumour
Solitary fibrous tumour (SFT) can be found in different 
locations, one of the most frequent is the pleura. Despite 
the majority of cases being benign, up to 40 % can be clas-
sified as malignant, which have a higher rate of local and 
distant recurrences [87, 88] (IV, B). The backbone of treat-
ment of localized SFT is surgical resection with wide mar-
gins. Adjuvant radiation therapy can be administered (IV, 
B). In metastatic or locally advanced SFT, chemotherapy 
following the common guidelines for STS could be admin-
istered (III B). Moreover, antiangiogenic agents such as 
sunitinib or the combination of temozolomide plus bevaci-
zumab constitute active options [89–91] (IV, B).
Inflammatory myofibroblastic tumour
Clinical manifestations of inflammatory myofibroblastic 
tumour (IMT) are secondary to local tumour. However, 
some patients can present systemic symptoms like fever 
and weight loss, as well as laboratory abnormalities like 
anaemia, thrombocytosis and polyclonal hypergamma-
globulinemia [92]. IMT is associated with rearrangements 
of the ALK (anaplastic lymphoma kinase) locus on chro-
mosome 2p23.13 [93]. In localized IMT the mainstay of 
treatment is wide resection. Generally, the surgery is cura-
tive and adjuvant chemotherapy is not recommended. In 
advanced IMT ALK-translocated, ALK-inhibitors, like cri-
zotinib, produce sustained responses and are recommended 
[93] (IV, B). Chemotherapy with different regimens has 
been classically used with variable efficacy (methotrexate 
plus vinorelbine, vincristine plus etoposide, cisplatin/car-
boplatin or ifosfamide regimens) [94, 95] and could consti-
tute a second-line option (IV B).
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